错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI

  • Pouria Yazdian Anari,
  • Aryan Zahergivar,
  • Nikhil Gopal,
  • Aditi Chaurasia,
  • Nathan Lay,
  • Mark W. Ball,
  • Baris Turkbey,
  • Evrim Turkbey,
  • Elizabeth C. Jones,
  • W. Marston Linehan,
  • Ashkan A. Malayeri

摘要

Introduction

Classification of clear cell renal cell carcinoma (ccRCC) growth rates in patients with Von Hippel–Lindau (VHL) syndrome has several ramifications for tumor monitoring and surgical planning. Using two separate machine-learning algorithms, we sought to produce models to predict ccRCC growth rate classes based on qualitative MRI-derived characteristics.

Material and Methods

We used a prospectively maintained database of patients with VHL who underwent surgical resection for ccRCC between January 2015 and June 2022. We employed a threshold growth rate of 0.5 cm per year to categorize ccRCC tumors into two distinct groups—‘slow-growing’ and ‘fast-growing’. Utilizing a questionnaire of qualitative imaging features, two radiologists assessed each lesion on different MRI sequences. Two machine-learning models, a stacked ensemble technique and a decision tree algorithm, were used to predict the tumor growth rate classes. Positive predictive value (PPV), sensitivity, and F1-score were used to evaluate the performance of the models.

Results

This study comprises 55 patients with VHL with 128 ccRCC tumors. Patients’ median age was 48 years, and 28 patients were males. Each patient had an average of two tumors, with a median size of 2.1 cm and a median growth rate of 0.35 cm/year. The overall performance of the stacked and DT model had 0.77 ± 0.05 and 0.71 ± 0.06 accuracies, respectively. The best stacked model achieved a PPV of 0.92, a sensitivity of 0.91, and an F1-score of 0.90.

Conclusion

This study provides valuable insight into the potential of machine-learning analysis for the determination of renal tumor growth rate in patients with VHL. This finding could be utilized as an assistive tool for the individualized screening and follow-up of this population.